New drug with radiation and chemo before surgery for advanced rectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial is testing a new drug combined with radiation and chemotherapy before surgery for locally advanced rectal cancer. The goal is to shrink the tumor and improve the chances of successful surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- Your rectal cancer must be a type that has not spread to distant organs (like the liver or lungs).
- You must not have had chemotherapy, radiation, or surgery for your rectal cancer before.
- Your cancer must have a specific marker called 'pMMR' or 'MSS' (your doctor can tell you this).
- You must be in good enough health to do light activities (like walking or light housework).
- Your heart's pumping function must be at least 50% (checked with an ultrasound or similar test).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment sequence for locally advanced rectal cancer: a short course of radiation followed by a combination of immunotherapy (cadonilimab) and chemotherapy (mFOLFOX6) before surgery. The goal is to shrink the tumor more effectively and potentially improve outcomes.
This trial tests a combination of short-course radiation, chemotherapy (CapeOx), and an immunotherapy drug (PD-1 inhibitor) for people with early-stage rectal cancer who have had a local excision but are at high risk of the cancer coming back. The goal is to avoid more extensive surgery while still effectively treating the cancer.
This trial tests a new combination of treatments (radiation, immunotherapy, and two chemotherapy drugs) given before surgery for people with a specific type of locally advanced rectal cancer that is close to the anus. The goal is to see if this approach is safe and effective.
This trial tests a new approach for people with locally advanced rectal cancer that has high-risk features. It combines short-course radiation with chemotherapy (CapeOX) and the immunotherapy drug toripalimab, with or without another drug called surufatinib, before surgery. The goal is to see if adding these drugs helps shrink the tumor and improve outcomes.
This trial tests combining standard chemotherapy and radiation with an immunotherapy drug (QL1706) before surgery for low rectal cancer. The goal is to see if this approach shrinks tumors more effectively and improves outcomes.
This trial tests whether a short course of radiation before surgery, combined with the immunotherapy drug envafolimab and the chemo regimen CAPEOX, works better for shrinking locally advanced rectal cancer. It is aimed at people whose tumor is not “MMR-deficient” (it is pMMR/MSS), and it asks participants to be able to return for repeated checkups and treatments.
Hear when a new Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.